EFTR
eFFECTOR Therapeutics (EFTR)
$
03About eFFECTOR Therapeutics (EFTR)
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). Its STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The company was founded by Kevan Shokat, Davide Ruggero, and Siegfried Reich on May 1, 2012 and is headquartered in Solana Beach, CA.
Details
Daily high
$0.04
Daily low
$0.02
Price at open
$0.04
52 Week High
$17.90
52 Week Low
$0.02
Market cap
131,700
Dividend yield
0.00%
Volume
20,804
Avg. volume
33,457
P/E ratio
.00
eFFECTOR Therapeutics News
Details
Daily high
$0.04
Daily low
$0.02
Price at open
$0.04
52 Week High
$17.90
52 Week Low
$0.02
Market cap
131,700
Dividend yield
0.00%
Volume
20,804
Avg. volume
33,457
P/E ratio
.00